Jaffetilchin Investment Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,925 shares of the company’s stock, valued at approximately $667,000.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. First Command Financial Services Inc. boosted its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. LeJeune Puetz Investment Counsel LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter valued at $136,000. Crestwood Advisors Group LLC acquired a new stake in shares of Eli Lilly and during the first quarter valued at $179,000. Alpha Windward LLC boosted its stake in shares of Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares in the last quarter. Finally, ARS Investment Partners LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter valued at $202,000. Institutional investors own 75.48% of the company’s stock.

Eli Lilly and Company (LLY) traded up 0.13% during midday trading on Thursday, reaching $81.93. The company had a trading volume of 3,688,344 shares. The firm has a market capitalization of $90.20 billion, a PE ratio of 35.31 and a beta of 0.34. The firm’s 50-day moving average price is $82.99 and its 200 day moving average price is $81.53. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.50% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the firm earned $0.86 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post $4.15 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

TRADEMARK VIOLATION NOTICE: “7,925 Shares in Eli Lilly and Company (LLY) Acquired by Jaffetilchin Investment Partners LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/03/jaffetilchin-investment-partners-llc-invests-667000-in-eli-lilly-and-company-lly-updated-updated-updated.html.

LLY has been the subject of several analyst reports. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Citigroup Inc. upped their price objective on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Jefferies Group LLC reiterated a “buy” rating and issued a $97.00 price target on shares of Eli Lilly and in a report on Monday, April 10th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $96.00 price objective on the stock in a research report on Wednesday, April 12th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Monday, April 17th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $88.37.

In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the transaction, the insider now directly owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.